About Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
INBX Key Statistics
| Current Price | $69.18 | Market Cap | $995 million |
|---|---|---|---|
| Daily Change | -2.09% | Volume | 90K |
| 52-Week High | $94.57 | 52-Week Low | $10.81 |
| Sector | Healthcare | Industry | Biotechnology |
INBX Price Performance
Inhibrx Biosciences, Inc. stock has returned -3.23% over the past day, -7.76% over the past week, -9.79% over the past month, and -9.94% over the past three months. The stock trades between a 52-week low of $10.81 and a high of $94.57.